Recipharm (RECI B)
Free
No email, no account, no signup.
Pulling latest news for Recipharm…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
NEUTRAL
Sentiment
6/10
Risk
6/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Recipharm is a CDMO providing pharmaceutical development and manufacturing services to pharma and biotech customers, with strengths in oral solid dose and sterile fill & finish. The company is privately owned (EQT) and delisted, meaning the shares are not publicly tradable.
Exchange
Nasdaq Stockholm
Type
Industrials
Sector
Pharmaceutical contract development and manufacturing (CDMO)
Market sentiment
Overall neutral-to-positive tone in industry/news tied to record revenue and strategic investments, with limited retail/social chatter due to private ownership.
Why NEUTRAL ?
- **REVIEW** because the company is **delisted** and cannot be bought directly on-exchange
- For exposure, **monitor a potential IPO/exit** or consider **indirect exposure via EQT**
- Operationally stable, but **biologics/ATMP execution** and macro remain key uncertainties
- No direct position possible; monitor IPO/exit 2026–2028 or indirect via EQT.
Recent News
- Since 2026-04-06, Recipharm has communicated (1) a 2025 sustainability update with a 74% reduction in Scope 2 emissions vs 2021 and 100% renewable electricity across all sites, (2) CEPI seed funding to Analysis Zero (a Recipharm subsidiary) to develop NMR-based real-time RNA vaccine quality testing, (3) IBT confirming PPQ manufacturing of IBP-9414 is progressing as planned at Recipharm with multiple batches completed, and (4) a Resyca joint venture with Medspray plus continued commercial visibility via industry events and technical publications (incl. HPAPI/analytical method development).
Bull case
- **Portfolio streamlining/divestments** may sharpen focus on core growth areas
- **New biologics/ATMP contracts** could support the growth narrative
- **Capacity investments** (e.g., pre-filled syringes/lyo) can drive positive newsflow
Unlock to read more →
Bear case
- **No direct public equity upside** because the company is delisted
- **Macro/geopolitical uncertainty** may reduce customer R&D/clinical spend
- **Lower disclosure** as a private company increases uncertainty
Unlock to read more →
Catalysts
15 Nov 2026 — HPAPI expansion in Spain
Dilution Risk
Assessment: Low
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Recipharm – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.